You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

Product menu

Amoxicillin-clavulanate: Continues to demonstrate favourable susceptibility against common pathogens of community-acquired infections*

Demonstrated in vitro susceptibility means that 90%-95% of your patients can expect to have a favourable therapeutic response.1

Survey of Antibiotic resistance (SOAR)

SOAR is an ongoing surveillance study monitoring antimicrobial resistance in the Middle East, Africa, Latin America, Asia-Pacific and the Commonwealth of Independent States countries, since 2002. Antimicrobial susceptibility of key respiratory pathogens (Streptococcus pneumoniae and Haemophilus influenzae) are being monitored to map the current local antimicrobial susceptibility patterns of these pathogens.2-11

SOAR helps in understanding local pathogen resistance to guide appropriate antibiotic prescription.3

SOAR’s robust and reliable susceptibility data collected from2-11:

isolates
centres_countries

How does SOAR monitor antibiotic susceptibility?

Clinical respiratory isolates were collected from patients with community-acquired respiratory tract infections. Organisms in the isolates are identified using conventional methods and minimum inhibitory concentrations (MIC) determined for the following antibiotics:2,4-11

  • Amoxicillin-clavulanate
  • Macrolides (azithromycin, clarithromycin, erythromycin)
  • Cephalosporins (cefaclor, cefixime, ceftriaxone, cefpodoxime, cefuroxime)
  • Fluoroquinolones (levofloxacin, moxifloxacin)
  • Clindamycin
  • Penicillin (ampicillin, amoxicillin)
  • Trimethoprim/sulfamethoxazole

Susceptibility testing was done using MIC breakpoints based on Clinical and Laboratory Standards Institute and/or European Committee on Antimicrobial Susceptibility Testing criteria.2,4-11

Amoxicillin-clavulanate: Still going strong, 40 years

Antimicrobial susceptibility of key respiratory tract pathogens*

*Results from the survey of antibiotic resistance in the Middle East (Pakistan, India). Susceptibility may vary with geography and time; please refer to local susceptibility data. Data for select antibiotics as per CLSI breakpoints are presented. Please refer to the original publication for a complete list of all antibiotics test.11 Susceptibility to azithromycin and clarithromycin can be predicted by testing erythromycin. CLSI guidelines assumes susceptibility to amoxicillin-clavulanate and cephalosporins based on penicillin susceptibility.12

Antimicrobial surveillance: 30 years of commitment to deliver high quality susceptibility data3

The SOAR programme is a follow-up of the Alexander Project to monitor antibiotic susceptibility that ran from 1992 to 2001 across 26 countries and successfully published over 46 papers of the robust data that it generated.

Value of Augmentin: SOAR
The Value of Antibiotic Surveillance

The ‘Survey of Antibiotic Resistance’ (SOAR) is a response to the serious emerging antimicrobial resistance and a way to share up-to-date data on antibiotic resistance levels to help the development of antibiotic prescribing guidelines and promote positive change.

LEARN MORE:

Need help with this product?

Request a contact

Need help

Stay Informed

Prescribing Information

References

  1. Doern GV, Brecher SM. The Clinical Predictive Value (or Lack Thereof) of the Results of In vitro Antimicrobial Susceptibility Tests. J Clin Microbiol 2011;49(9_Suppl):S11-4.
  2. Torumkuney D, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2015–17 in Pakistan: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. J Antimicrob Chemother 2020;75(Suppl 1):i76-i87.
  3. GSK - Survey of Antibiotic Resistance (SOAR) - AMR Industry Alliance. AMR Industry Alliance. Available at: https://www.amrindustryalliance.org/case-study/gsks-survey-of-antibiotic-resistance-soar. Last accessed: 23 November 2022.
  4. Torumkuney D, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2015-18 in Tunisia, Kenya and Morocco: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. J Antimicrob Chemother 2020;75(Suppl 1):i2-i18.
  5. Torumkuney D, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2014–16 in Greece. J Antimicrob Chemother 2018;73(Suppl 5):v36–v42.
  6. Torumkuney D, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2016–18 in Vietnam, Cambodia, Singapore and the Philippines: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. J Antimicrob Chemother 2020;75(Suppl 1): i19-i42.
  7. Torumkuney D, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2015–17 in Latin America (Argentina, Chile and Costa Rica): data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. J Antimicrob Chemother 2020;75(Suppl 1):i43-i59.
  8. Torumkuney D, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2015–17 in the Middle East (Kuwait, Lebanon and Saudi Arabia): data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. J Antimicrob Chemother 2020;75(Suppl 1):i60-i75.
  9. Torumkuney D, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2015–17 in Turkey: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. J Antimicrob Chemother 2020;75(Suppl 1):i88-i99.
  10. Torumkuney D, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2015–17 in Ukraine: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. J Antimicrob Chemother 2020;75(Suppl 1):i100-i111.
  11. Torumkuney D, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2012–14 in Thailand, India, South Korea and Singapore. J Antimicrob Chemother 2016;71 Suppl 1: i3–i19.
  12. Clinical & Laboratory Standards Institute. M100, Performance Standards for Antimicrobial Susceptibility Testing, 32nd edition. Available from: edaptivedocs.net. Last accessed 15 August 2022.

Prepared by GSK. For adverse events reporting or product complaints contact GSK by email fv.aecaricam@gsk.com or phone : Jamaica +1(876) 630-2074.
GSK Offices, Oceania Business Plaza Torre 1000 floor 34. Panama, Republic of Panama, C.A. All rights reserved GSK. The complete prescribing information and/or reference are available upon request. Trade marks are owned by or licensed to the GSK group of companies. Material Exclusive for Healthcare Professionals.

Augmentin is a registered trademark of the GlaxoSmithKline group of companies.

PM-RCH-ACA-WCNT-230005 | Approval date: January 2024. Expiration date: January 2026